Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Lisata Therapeutics, Inc.
Boehringer Ingelheim
Novartis
Agenus Inc.
Bristol-Myers Squibb
Celgene
Gilead Sciences
Hoffmann-La Roche
Incyte Corporation
Oncolytics Biotech
Hoffmann-La Roche
Pfizer
Cornerstone Pharmaceuticals
Spectrum Pharmaceuticals, Inc